Multiple Myeloma : Minimal Residual Disease Testing as an End Point Treatment

1:03:00
 
Share
 

Manage episode 185973710 series 1143960
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.
Most multiple myeloma patients, even those in complete response, may show signs of relapse at some point of time. So, testing and quantifying Minimal Residual Disease (MRD) has become essential to obtain better prognostic correlations. Researchers believe that MRD testing could help them compare myeloma therapy strategies, evaluate new treatments faster, and guide treatment decisions. Our myeloma panelists are talking to Dr. Ola Landgren, a lead researcher in the field, on what MRD testing could mean to your treatment, and about how MRD testing could become a new and earlier end-point in myeloma treatment.

159 episodes available. A new episode about every 20 days averaging 61 mins duration .